Aesthetic medical device company Soliton Inc. (SOLY:NASDAQ), which states that it utilizes a novel and proprietary platform technology licensed from the University of Texas on behalf of the MD Anderson Cancer Center, today announced that the company's preliminary proof of concept study results using its Rapid Acoustic Pulse (RAP) device for the treatment of fibrotic (keloid and hypertrophic) scars has been selected for presentation via abstract at the American Society for Dermatologic Surgery Annual Meeting on October 24, 2019, in Chicago, Illinois.
Christopher Capelli, MD, founder, president and CEO of Soliton, commented, "We are pleased to be presenting the results from our initial follow-up visit to attendees at this important dermatology conference...We look forward to being able to share these results with our shareholders and all interested parties as quickly as possible after the conference. We view this proof-of-concept trial as the starting point for demonstrating that our technology could impact other fibrotic disorders. The same mechanism of action at work to reduce keloid and hypertrophic scars could likely extend to such indications as capsular contraction, Peyrone's Disease, and even liver fibrosis."
The company states in the announcement that "fibrotic scars, such as keloid and hypertrophic scars, represent wound healing gone awry." The firm further explains that "existing published research suggests that factors relating to the wound-healing environment (including tension at the boundary of the scar) can cause fibroblasts to become stuck in a hyper-productive loop, unable to stop the production of collagen that leads to the thickened, raised and dense structures often associated with these fibrotic scars."
Soliton reports that the American Osteopathic College of Dermatology estimates that keloids affect around 10% of people, whereas hypertrophic scars are more common and affect men and women from any racial group equally, although people between the ages of 10 and 30 years old are more likely to be affected.
A few days ago the Soliton announced that its article, "Increased Tattoo Fading in a Single Laser Tattoo Removal Session Enabled By a Rapid Acoustic Pulse Device: A Prospective Clinical Trial," will be published in the next issue of Lasers in Surgery and Medicine journal. LSM will feature the article as its Editors Choice paper.
Dr. Capelli added, "We are truly pleased to have our article published in the Lasers in Surgery and Medicine journal...given the high value Soliton places on developing its products with a foundation of real science. Publication in this journal is true validation of our technology and trial results and selection by the editors for the 'Editor's Choice' paper is even more gratifying."
Just one week ago the firm announced it has completed all patient treatments in the keloid scar proof-of-concept trial. The company advised that the study, which was conducted by Dr. Brenda LaTowsky, Board Certified Dermatologist at Clear Dermatology & Aesthetic Center in Scottsdale, Ariz., was designed to evaluate the safety and efficacy for all patients through a 12-week time point.
Dr. Capelli noted, "We eagerly anticipate the follow-up visits with these patients. Demonstrating success in this trial would lay a foundation for Soliton to pursue treatment for many other fibrotic disorders."
Soliton, which is based in Houston, Tex., advises that its first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The firm states that it is actively engaged in bringing the Rapid Acoustic Pulse device to the market, and believes its proprietary method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods.
Soliton has a market capitalization of about $184.1 million with 16.09 million shares outstanding. The stock has a 52-week price range of $4.12–29.00. This morning, SOLY shares opened at $11.53 (+$0.09, +0.79%) over yesterday's $11.44 closing price. The stock has traded today between $11.53 and $12.85/share and is currently trading at $12.58 (+$1.14, +9.97%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
